Faron Pharmaceuticals Oy

Established in Turku, Finland, in 2003, Faron Pharmaceuticals Oy operates as a clinical-stage biotechnology firm dedicated to the discovery and advancement of novel pharmaceutical solutions. The company's core focus lies in harnessing immune modulation to develop proprietary drug candidates addressing significant unmet medical needs. Their pipeline spans critical areas such as immuno-oncology, organ safeguarding, and regenerative medicine. Among its leading therapeutic candidates is Traumakine, an intravenous interferon beta-1a treatment under investigation for conditions including acute respiratory distress syndrome (ARDS), COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury. Another key asset is Bexmarilimab, an innovative precision cancer immunotherapy designed to target solid tumors, non-small cell lung carcinoma, and hematological malignancies. Additionally, Faron is developing Haematokine, a new chemical entity acting as an AOC3 inhibitor, aimed at treating hematological malignancies and bone marrow-related conditions.